Abstract: A method includes administering to a subject (i) a pharmacological agent that binds to receptors in a subject, and (ii) a radiotracer to alter a functional state and occupancy of the receptors in the subject. The method also includes acquiring imaging data of brain tissue in the subject comprising the receptors. The imaging data include positron emission tomography (PET) imaging data and functional magnetic resonance (fMR) imaging data. The method further includes calculating (i) a dynamic response of the functional state to the pharmacological agent and the radiotracer based on the fMR imaging data, and (ii) a dynamic response of the receptor occupancy to the pharmacological agent and the radiotracer based on the PET imaging data.

Abstract: The invention provides methods for inhibiting psychostimulant-induced or nicotine-induced craving of additional psychostimulants (e.g., cocaine or amphetamine) or nicotine. In these methods, D1-like antagonists or D1-like agonists are administered to a patient dependent on psychostimulant drugs or nicotine and therefore susceptible to, or suffering from, such a craving. Also disclosed is an animal model system useful for measuring the ability of test compounds to inhibit psychostimulant-induced or nicotine-induced cravings in humans.

Abstract: The invention provides methods for inhibiting psychostimulant-induced or nicotine-induced craving of additional psychostimulants (e.g., cocaine or amphetamine) or nicotine. In these methods, D1-like antagonists or D1-like agonists are administered to a patient dependent on psychostimulant drugs or nicotine and therefore susceptible to, or suffering from, such a craving. Also disclosed is an animal model system useful for measuring the ability of test compounds to inhibit pyschostimulant-induced or nicotine-induced cravings in humans.